Name: Ep175: Andy Scharenberg on in vivo CAR-T cell therapies by The Long Run with Luke Timmerman
Duration: 1 h 10 min 46 s
Description: Andy Scharenberg, CEO of Seattle-based Umoja Biopharma, on developing in vivo CAR-T cell therapies.

Alnylam Pharmaceuticals chief scientific officer Kevin Fitzgerald on the past, present & future of RNA interference medicines.

Ep169: Kevin Fitzgerald on the Past & Future of RNAi Medicines

David Schenkein, general partner at GV, on investing in the future of biotech.

Ep170: David Schenkein on Investing in the Future of Biotech

Ram Aiyar, CEO of Cambridge, Mass.-based Korro Bio, on RNA editing medicines.

Ep171: Ram Aiyar on RNA Editing Medicines

Mostafa Ronaghi, co-founder and executive board member of Cellanome, on developing technology to look at live cells and cellular interactions at scale. 

Ep172: Mostafa Ronaghi on Studying Live Cells at Scale

Robert Blum, CEO of South San Francisco-based Cytokinetics, on building a fully integrated biopharma to treat muscle disorders.

Ep173: Robert Blum on Building a Fully Integrated Biopharma For Muscle Disorders

Najat Khan, chief R&D and chief commercial officer of Recursion, on using technology to improve drug discovery.

Ep174: Najat Khan on the TechBio Movement

Andy Scharenberg, CEO of Seattle-based Umoja Biopharma, on developing in vivo CAR-T cell therapies.

Ep175: Andy Scharenberg on in vivo CAR-T cell therapies

David Roblin, CEO of London-based Relation Therapeutics, on building a techbio discovery company.

Ep176: David Roblin on Building a TechBio Company

Kevin Parker, co-founder and CEO of South San Francisco-based Cartography Biosciences, on finding new targets for cancer drugs.

Ep177: Kevin Parker on Finding Targets for Cancer Drugs

Kevin Parker, CEO of Cartography Biosciences, on finding new cancer drug targets.

Ep177: Kevin Parker on Finding Cancer Drug Targets

"The Long Run"

Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous. 

Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.

Ep175: Andy Scharenberg on in vivo CAR-T cell therapies

The Long Run with Luke Timmerman

Related tracks